Other names: Saphnelo
Categories: Prescription Medication
Description: Anifrolumab (brand name Saphnelo) is a monoclonal antibody approved for the treatment of moderate to severe systemic lupus erythematosus (SLE) in patients who are autoantibody-positive and have incomplete response to standard therapy. It targets the type I interferon receptor, blocking a key inflammatory pathway involved in lupus. Anifrolumab is given as a monthly IV infusion and has been shown to reduce disease activity, flares, and corticosteroid use in clinical trials. It is not approved for lupus nephritis or CNS lupus. Common side effects include respiratory infections and infusion reactions, and it should be used with caution in patients with chronic infections.
Treatment For:
AI generated Summary: Based on the provided information, there are no reviews or ratings available for the treatment 'Anifrolumab' against the disease 'Systemic Lupus Erythematosus'. Without any user feedback or author review, it is not possible to determine the effectiveness of this treatment from the given data.
The information, including but not limited to, text, graphics, images and other material contained on this website/app are for informational purposes only. No material on this site/app is intended to be a substitute for professional medical advice, diagnosis or treatment. Always seek the advice of your physician or other qualified healthcare provider with any questions you may have regarding a medical condition or treatment and before undertaking a new health care regimen, and never disregard professional medical advice or delay in seeking it because of something you have read on this website/app.
Copyright © 2025,Curbside and related marks are registered trademarks of Curbside Tech Inc.
